Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bioequivalence of an Alternate Ixekizumab Formulation Compared to the Commercial Formulation in Healthy Subjects

Next Previous
X
Search
Trial Profile

Bioequivalence of an Alternate Ixekizumab Formulation Compared to the Commercial Formulation in Healthy Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 26 Apr 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ixekizumab (Primary)
  • Indications Ankylosing spondylitis; Bullous pemphigoid; Erythrodermic psoriasis; Juvenile rheumatoid arthritis; Pityriasis rubra pilaris; Plaque psoriasis; Psoriatic arthritis; Pustular psoriasis; Pyoderma gangrenosum; Spondylarthritis; Varicose ulcer
  • Focus Pharmacokinetics
  • Sponsors Eli Lilly and Company

    • Most Recent Events

    • 12 Apr 2022 Primary endpoint (PK: Area Under the Concentration Versus Time Curve (AUC) of Ixekizumab) has been met according to the results published in the Advances in Therapy
    • 12 Apr 2022 Primary endpoint (Pharmacokinetics (PK): Maximum Concentration (Cmax) of Ixekizumab) has been met according to the results published in the Advances in Therapy
    • 12 Apr 2022 Results published in the Advances in Therapy

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top